Groundbreaking ev-302 trial significantly extends overall survival and progression-free survival in patients treated with padcev® (enfortumab vedotin-ejfv) and keytruda® (pembrolizumab) in first-line advanced bladder cancer

– risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – enfortumab vedotin plus pembrolizumab improved median overall survival by more than 15 months vs. chemotherapy – – results will form the basis of global regulatory submissions – tokyo and bothell, wash.
SGEN Ratings Summary
SGEN Quant Ranking